摘要
乙型肝炎病毒感染在我国是一个重要的公共卫生问题。由于抗病毒药物的出现,乙型肝炎的临床管理已经卓有成效。乙型肝炎长期治疗结局和抗病毒药物的停药指标等相关问题是当前临床实践中面临的亟待解决的问题。为此,必须扎扎实实进一步回归临床研究,以终为始,建立大型长期临床研究队列。相信,通过几代人坚持不懈的努力,这些难题终将找到答案。
Chronic hepatitis B is a serious public health issue in China. The clinical management of hepatitis B is effective with the emergence of antiviral agents. The outcome of long-term therapy and nucleos(t) ide analogues stopping rules are currently unresolved issues and tmmet needs. Thus, we need to pay more attention to clinical research to build large-sample and long-term follow-up cohorts and begin with the end in mind. We believe that the way to resolve the issues above will be found with the efforts of generations.
出处
《中华肝脏病杂志》
CAS
CSCD
北大核心
2017年第7期481-484,共4页
Chinese Journal of Hepatology
关键词
肝炎
乙型
治疗
治疗
临床研究性
临床结局
Hepatitis B
Therapy
Therapies, investigational
Clinical outcome